Related Experiment Video
Updated: Jul 16, 2026
08:25
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
Statins and the risk of pneumonia: a population-based, nested case-control study
Raymond G Schlienger1, David S Fedson, Susan S Jick
1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland.
Pharmacotherapy
|February 24, 2007
Summary
Current statin use significantly reduces the risk of fatal pneumonia. This study found statins may lower pneumonia risk, especially for severe cases.
Area of Science:
- Cardiovascular Medicine
- Infectious Disease Epidemiology
- Pharmacological Research
Background:
- Statins are widely prescribed for hyperlipidemia.
- Pneumonia remains a significant cause of morbidity and mortality.
- The potential impact of statins on pneumonia risk is not fully understood.
Purpose of the Study:
- To investigate the association between statin use and pneumonia outcomes.
- To analyze the effect of statins on pneumonia-related outpatient visits, hospitalizations, and deaths.
Main Methods:
- Population-based retrospective nested case-control analysis.
- Utilized the UK General Practice Research Database.
- Included over 134,000 patients, comparing statin users with non-users and hyperlipidemic controls.
Main Results:
- Current statin users showed a significantly reduced risk of fatal pneumonia (aOR 0.47).
- A trend towards reduced risk for uncomplicated pneumonia and hospitalization with survival was observed but not statistically significant.
- Past statin use and fibrate use were not associated with reduced pneumonia risk.
Conclusions:
- Current statin use is linked to a lower risk of pneumonia.
- The protective effect of statins against pneumonia is most pronounced in preventing fatal cases.
Related Concept Videos
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...